Bayer AG announces varied Q3 performance while maintaining FY25 forecast
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Source: SeekingAlpha
Earnings Performance: Bayer AG reported a Q3 Non-GAAP EPS of Є0.57, exceeding expectations by Є0.25, while revenue declined by 3.1% year-over-year to Є9.66 billion, missing estimates by Є60 million.
EBITDA and Cash Flow: EBITDA before special items increased by 20.8% to Є1.511 billion, but free cash flow fell by 48.1% to Є596 million due to higher settlement payments.
Guidance Update: The company confirmed its 2025 group guidance, projecting Consumer Health sales growth between -1% to +1%, a revision from the previous forecast of 2% to 5%.
Litigation Provisions: Bayer anticipates increased special items in full-year Group EBITDA and EBIT due to additional provisions for litigations, adjusting forecasts to reflect expected losses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
